NASDAQ:MEIP MEI Pharma (MEIP) Stock Forecast, Price & News $6.98 0.00 (0.00%) (As of 12:55 PM ET) Add Compare Share Share Today's Range$6.77▼$6.9950-Day Range$5.04▼$7.5852-Week Range$4.00▼$8.68Volume11,834 shsAverage Volume55,137 shsMarket Capitalization$46.49 millionP/E RatioN/ADividend YieldN/APrice Target$29.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability MEI Pharma MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside329.3% Upside$29.67 Price TargetShort InterestBearish4.41% of Float Sold ShortDividend StrengthN/ASustainability-0.49Upright™ Environmental ScoreNews Sentiment0.61Based on 17 Articles This WeekInsider TradingAcquiring Shares$1.05 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($4.89) to ($4.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector370th out of 976 stocksPharmaceutical Preparations Industry152nd out of 448 stocks 3.0 Analyst's Opinion Consensus RatingMEI Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.67, MEI Pharma has a forecasted upside of 329.3% from its current price of $6.91.Amount of Analyst CoverageMEI Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.41% of the float of MEI Pharma has been sold short.Short Interest Ratio / Days to CoverMEI Pharma has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in MEI Pharma has recently increased by 3.61%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMEI Pharma does not currently pay a dividend.Dividend GrowthMEI Pharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMEI Pharma has received a 74.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for MEI Pharma is -0.49. Previous Next 3.1 News and Social Media Coverage News SentimentMEI Pharma has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for MEI Pharma this week, compared to 1 article on an average week.Search Interest2 people have searched for MEIP on MarketBeat in the last 30 days. MarketBeat Follows1 people have added MEI Pharma to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MEI Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,050,411.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.16% of the stock of MEI Pharma is held by insiders.Percentage Held by Institutions41.92% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MEI Pharma are expected to grow in the coming year, from ($4.89) to ($4.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MEI Pharma is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MEI Pharma is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMEI Pharma has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MEI Pharma (NASDAQ:MEIP) StockMEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Read More MEIP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEIP Stock News HeadlinesOctober 2, 2023 | finance.yahoo.comMEI Pharma Adopts Limited-Duration Stockholder Rights PlanSeptember 30, 2023 | americanbankingnews.comStifel Nicolaus Lowers MEI Pharma (NASDAQ:MEIP) Price Target to $9.00October 3, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 30, 2023 | americanbankingnews.comMEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.comSeptember 30, 2023 | americanbankingnews.comQ1 2024 EPS Estimates for MEI Pharma, Inc. Increased by Brookline Capital Management (NASDAQ:MEIP)September 29, 2023 | finance.yahoo.comAll You Need to Know About MEI Pharma, Inc. (MEIP) Rating Upgrade to Strong BuySeptember 28, 2023 | stockhouse.comMEI Pharma Issues Statement Regarding Anson and Cable Car's Opportunistic ActionsSeptember 28, 2023 | finance.yahoo.comMEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic ActionsOctober 3, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 27, 2023 | finance.yahoo.comMEI Pharma, Inc. (NASDAQ:MEIP) Q4 2023 Earnings Call TranscriptSeptember 27, 2023 | finance.yahoo.comQ4 2023 MEI Pharma Inc Earnings CallSeptember 26, 2023 | finance.yahoo.comAnson And Cable Car Send Letter to MEI Pharma StockholdersSeptember 26, 2023 | finance.yahoo.comMEI Pharma Reports Fiscal Year 2023 Results and Operational HighlightsSeptember 26, 2023 | finance.yahoo.comAnson Funds Management LP Acquires Shares in MEI Pharma IncSeptember 26, 2023 | americanbankingnews.comAnson Funds Management Lp Acquires 48,060 Shares of MEI Pharma, Inc. (NASDAQ:MEIP) StockSeptember 26, 2023 | americanbankingnews.comMEI Pharma, Inc. (NASDAQ:MEIP) Major Shareholder Anson Funds Management Lp Buys 48,060 SharesSeptember 26, 2023 | americanbankingnews.comMEI Pharma, Inc. (NASDAQ:MEIP) Receives Consensus Recommendation of "Hold" from BrokeragesSeptember 25, 2023 | benzinga.comEarnings Outlook For MEI PharmaSeptember 24, 2023 | americanbankingnews.comAnson Funds Management Lp Purchases 120,000 Shares of MEI Pharma, Inc. (NASDAQ:MEIP) StockSeptember 24, 2023 | americanbankingnews.comMEI Pharma (MEIP) Set to Announce Quarterly Earnings on TuesdaySeptember 23, 2023 | finance.yahoo.comAnson Funds Management LP Acquires Additional Shares in MEI Pharma IncSeptember 21, 2023 | finance.yahoo.comMEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023September 18, 2023 | markets.businessinsider.comSTOCKHOLDER ALERT: Abbott Cooper PLLC Announces Investigation Into Possible Violations of Fiduciary Duty by the Board of Mei Pharma, Inc.September 18, 2023 | markets.businessinsider.comCORRECTION: Abbott Cooper PLLC Announces Investigation Into Possible Violations of Fiduciary Duty by the Board of Mei Pharma, Inc.September 18, 2023 | finance.yahoo.comMEI Pharma Confirms Receipt of Director Nominations From Anson and Cable CarAugust 16, 2023 | finance.yahoo.comMEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal CancerJuly 26, 2023 | bizjournals.comCambridge biotech cuts most staffers after merger falls apartSee More Headlines Receive MEIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address MEIP Company Calendar Last Earnings11/10/2021Today10/03/2023Next Earnings (Estimated)11/13/2023Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MEIP Previous SymbolNASDAQ:MSHL CUSIPN/A CIK1262104 Webwww.meipharma.com Phone(858) 369-7100Fax302-655-5049Employees46Year FoundedN/APrice Target and Rating Average Stock Price Forecast$29.67 High Stock Price Forecast$40.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+325.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,840,000.00 Net Margins-65.22% Pretax Margin-65.22% Return on Equity-92.47% Return on Assets-23.63% Debt Debt-to-Equity RatioN/A Current Ratio5.29 Quick Ratio5.29 Sales & Book Value Annual Sales$48.82 million Price / Sales0.95 Cash FlowN/A Price / Cash FlowN/A Book Value$3.70 per share Price / Book1.89Miscellaneous Outstanding Shares6,660,000Free Float6,253,000Market Cap$46.49 million OptionableOptionable Beta0.83 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. David M. Urso B.A. (Age 59)Esq., J.D., CEO, Pres & Director Comp: $665.65kDr. Richard G. Ghalie (Age 65)Chief Medical Officer Comp: $581.53kMr. Justin J. File (Age 53)CFO & Corp. Sec. Mr. Eugene ParkVP of MarketingMs. Anne FreseChief People OfficerDr. Robert D. Mass (Age 69)Strategic Advisor Mr. David A. Walsey J.D.L.L.M., Sr. VP of Corp. AffairsMs. Yomara Gomez-NaidenSr. VP of QualityMore ExecutivesKey CompetitorsImmunoPrecise AntibodiesNASDAQ:IPASELLAS Life Sciences GroupNASDAQ:SLSDianthus TherapeuticsNASDAQ:DNTHRezoluteNASDAQ:RZLTHookipa PharmaNASDAQ:HOOKView All CompetitorsInsiders & InstitutionsAnson Funds Management LpBought 48,060 shares on 9/22/2023Total: $329,211.00 ($6.85/share)Anson Funds Management LpBought 120,000 shares on 9/20/2023Total: $721,200.00 ($6.01/share)Boxer Capital LLCSold 2,767,437 shares on 8/15/2023Ownership: 2.187%Wells Fargo & Company MNSold 225,748 shares on 8/15/2023Ownership: 0.151%Citadel Advisors LLCSold 5,100 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions MEIP Stock - Frequently Asked Questions Should I buy or sell MEI Pharma stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares. View MEIP analyst ratings or view top-rated stocks. What is MEI Pharma's stock price forecast for 2023? 6 equities research analysts have issued 12-month price objectives for MEI Pharma's shares. Their MEIP share price forecasts range from $9.00 to $40.00. On average, they predict the company's share price to reach $29.67 in the next year. This suggests a possible upside of 325.0% from the stock's current price. View analysts price targets for MEIP or view top-rated stocks among Wall Street analysts. How have MEIP shares performed in 2023? MEI Pharma's stock was trading at $4.8720 at the beginning of 2023. Since then, MEIP stock has increased by 43.3% and is now trading at $6.98. View the best growth stocks for 2023 here. When is MEI Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our MEIP earnings forecast. How were MEI Pharma's earnings last quarter? MEI Pharma, Inc. (NASDAQ:MEIP) released its earnings results on Wednesday, November, 10th. The company reported ($2.60) EPS for the quarter, meeting the consensus estimate of ($2.60). The business had revenue of $13.39 million for the quarter, compared to the consensus estimate of $9.98 million. MEI Pharma had a negative trailing twelve-month return on equity of 92.47% and a negative net margin of 65.22%. When did MEI Pharma's stock split? Shares of MEI Pharma reverse split on Monday, April 17th 2023. The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of MEI Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), OPKO Health (OPK), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD). What is MEI Pharma's stock symbol? MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP." How do I buy shares of MEI Pharma? Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MEI Pharma's stock price today? One share of MEIP stock can currently be purchased for approximately $6.98. How much money does MEI Pharma make? MEI Pharma (NASDAQ:MEIP) has a market capitalization of $46.49 million and generates $48.82 million in revenue each year. The company earns $-31,840,000.00 in net income (profit) each year or ($4.63) on an earnings per share basis. How can I contact MEI Pharma? MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.meipharma.com. The company can be reached via phone at (858) 369-7100, via email at investor@meipharma.com, or via fax at 302-655-5049. This page (NASDAQ:MEIP) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.